Tuberculosis Diagnostics: AFB Smear, GeneXpert MTB/RIF Ultra, Culture, and IGRA vs TST

Tuberculosis (TB), caused by the Mycobacterium tuberculosis complex (M. tuberculosis, M. bovis, M. africanum), remains a leading global cause of infectious mortality. The cell wall of M. tuberculosis possesses a unique, highly lipid-rich architecture containing long-chain mycolic acids (C₆₀–C₉₀), arabinogalactans, and lipoarabinomannan. This waxy envelope confers resistance to Gram staining, humoral lysis, and common disinfectants, rendering the organism acid-fast (it retains primary carbolfuchsin stain upon destaining with acidified alcohol).

The clinical spectrum spans a continuum:

1. Latent Tuberculosis Infection (LTBI): Viable mycobacteria are contained within calcified, fibrocaseous granulomas (Ghon focus, Ranke complex) by persistent host CD4+ T-cell and macrophage cell-mediated immunity (TNF-α, IFN-γ). The patient is asymptomatic, non-contagious, and has normal radiography.
2. Active Tuberculosis Disease: Breakdown of immune containment leads to caseous liquefaction, cavitation, and massive extracellular bacillary multiplication (10⁷–10⁹ bacilli in cavitary lesions). The patient is symptomatic, contagious, and has positive microbiological examinations.

Diagnostic modalities are dichotomized based on target:

• Direct Microbiological Diagnostics (Active TB): AFB Smear microscopy, GeneXpert MTB/RIF Ultra automated real-time PCR, Line Probe Assays (LPA), and automated liquid Mycobacteria Growth Indicator Tube (MGIT) culture.
• Indirect Immunological Biomarkers (LTBI / Immunological Sensitization): Tuberculin Skin Test (TST / Mantoux) and Interferon-Gamma Release Assays (IGRA: QuantiFERON-TB Gold Plus, T-SPOT.TB).

Specimen quality directly determines diagnostic yield:

1. Suspected Active Pulmonary Tuberculosis: Unexplained chronic cough > 2–3 weeks, hemoptysis, fevers, drenching night sweats, weight loss, anorexia, or apical cavitary infiltrates on chest radiography.
2. Suspected Extrapulmonary Tuberculosis: Subacute/chronic lymphocytic meningitis, unexplained pleural/pericardial/ascitic exudates, chronic cervical lymphadenopathy (scrofula), vertebral destructive lesions (Pott disease).
3. Screening for Latent TB Infection (LTBI):

• Prior to initiating biologic immunosuppressants (anti-TNF agents: infliximab, adalimumab, etanercept).
• Solid organ or hematopoietic stem cell transplant candidates.
• Patients initiating chronic high-dose systemic corticosteroid therapy (≥ 15 mg/day prednisone equivalent for > 1 month).
• Close household contacts of active infectious pulmonary TB cases.
• Healthcare workers and correctional facility staff upon hire.

Step 1: Determine Clinical Objective: Active Disease vs Latent Screening
   ├─ Patient has symptoms, abnormal X-ray ──> ORDER DIRECT MICROBIOLOGY (Sputum GeneXpert + Smear + Culture)
   └─ Patient is asymptomatic, pre-biologic ─> ORDER IMMUNOLOGICAL TEST (IGRA preferred over TST)

Step 2: Interpret GeneXpert MTB/RIF Ultra Result
   ├─ MTB DETECTED / Rif Resistance NOT Detected ──> Start Standard 4-Drug Therapy (HRZE)
   ├─ MTB DETECTED / Rif Resistance DETECTED ──────> Initiate MDR-TB Regimen + Airborne Isolation + Send 2nd-Line LPA
   ├─ MTB DETECTED / Trace (in CSF, paucibacillary) ─> Regard as TRUE POSITIVE for TB in sterile sites / HIV
   └─ MTB NOT Detected ────────────────────────────> Does NOT rule out TB if clinical suspicion is high (wait for MGIT)

Step 3: Correlate Smear Microscopy with GeneXpert
   ├─ Smear (+) / GeneXpert (+) ───────────────> Highly contagious active pulmonary M. tuberculosis
   ├─ Smear (+) / GeneXpert (-) ───────────────> Suspect Non-Tuberculous Mycobacteria (NTM, e.g. M. avium, M. kansasii)
   └─ Smear (-) / GeneXpert (+) ───────────────> Paucibacillary active TB (caught by high molecular sensitivity)

Step 4: Interpret IGRA / TST (Latent TB Testing)
   ├─ IGRA Positive / Chest X-ray Normal ──────> Treat as LTBI (e.g. 3HP: 3 months Isoniazid + Rifapentine)
   ├─ IGRA Positive / Chest X-ray Abnormal ────> STOP! Must rule out Active TB (sputum GeneXpert) BEFORE LTBI therapy
   └─ IGRA Indeterminate (Low Mitogen Control) ─> Severe T-cell immunosuppression or assay handling error; retest

• MDR-TB (Multidrug-Resistant TB): Resistance to at least Isoniazid (H) and Rifampicin (R) simultaneously.
• Pre-XDR-TB: MDR-TB that is also resistant to any fluoroquinolone (levofloxacin or moxifloxacin).
• XDR-TB (Extensively Drug-Resistant TB): MDR-TB that is resistant to any fluoroquinolone PLUS at least one additional Group A second-line agent (bedaquiline or linezolid).

• Occurs when an environmental Non-Tuberculous Mycobacteria (NTM) (e.g., Mycobacterium avium complex, M. abscessus, M. kansasii) is present.
• The organism is acid-fast on ZN smear, but lacks the specific M. tuberculosis complex DNA insertion sequences (IS6110/IS1081).
• Requires mycobacterial species identification via DNA probe or MALDI-TOF mass spectrometry.

• In patients with advanced HIV infection (CD4 < 100/µL), active overwhelming miliary/meningeal TB, severe malnutrition, or systemic corticosteroids, circulating T-cells are depleted or exhausted.
• Stimulation with phytohemagglutinin (mitogen positive control) fails to generate adequate IFN-γ, producing an Indeterminate IGRA result.

1. Fluoroquinolone Pre-Treatment: Empiric outpatient use of respiratory fluoroquinolones (levofloxacin, moxifloxacin) for presumed bacterial pneumonia temporarily suppresses M. tuberculosis growth, causing delayed diagnosis, false-negative cultures, and rapid induction of fluoroquinolone resistance!
2. Prior BCG Vaccination: Causes false-positive TST induration that persists for 5–15 years post-immunization. In contrast, IGRA is completely unaffected by BCG vaccination because ESAT-6 and CFP-10 are absent in all BCG strains.
3. Assay Incubation Delays for IGRA: QuantiFERON blood collection tubes must be incubated at 37^°C within 16 hours of venipuncture; delays destroy viable T-cell function, leading to false-negative or indeterminate results.

• Using IGRA or TST to Diagnose Active TB: This is one of the commonest medical errors. A positive IGRA only denotes past immunological exposure; it cannot distinguish active disease from dormant latent infection or cured past TB. Up to 15–25% of patients with severe active TB have false-negative IGRAs!
• Dismissing Negative Smears: A negative sputum AFB smear excludes only high-burden, highly contagious cavitary disease; it misses up to 40–50% of culture-confirmed active pulmonary TB.
• GeneXpert Cannot Measure Treatment Response: GeneXpert detects DNA from both living and dead bacilli. Sputum GeneXpert can remain positive for months or years after successful cure. Monitoring bacteriological response during therapy must be performed with sputum smear microscopy and liquid culture, NEVER GeneXpert!

> [!CAUTION] > Immediate Airborne Isolation and Public Health Notifications: > 1. Smear-Positive Pulmonary Cavitary TB: Extreme transmission risk; requires airborne infection isolation (negative-pressure room, ≥ 12 air changes/hour, N95 respirators for all staff). > 2. Rifampicin Resistance Detected on GeneXpert: Presumptive MDR-TB; immediate second-line testing, infectious disease consultation, and specialized regimen initiation. > 3. Suspected Tuberculous Meningitis: High mortality and stroke risk; do not wait for culture confirmation—initiate antituberculous therapy and dexamethasone immediately.

• Target Antigens of IGRA: ESAT-6 (early secretory antigenic target 6) and CFP-10 (culture filtrate protein 10) are located in the RD1 genomic region of M. tuberculosis, which is entirely absent from all M. bovis BCG vaccines and almost all NTMs (exceptions: M. kansasii, M. marinum, M. szulgai).
• Rifampicin Resistance Gene: Conferred by point mutations in the rpoB gene (encoding the beta-subunit of bacterial RNA polymerase).
• Isoniazid Resistance Genes: Conferred by mutations in katG (high-level resistance; catalase-peroxidase enzyme that activates the pro-drug isoniazid) or the inhA promoter (low-level resistance; cross-resistant to ethionamide).
• Adenosine Deaminase (ADA): Pleural fluid ADA ≥ 40 U/L combined with a lymphocyte/neutrophil ratio ≥ 0.75 has a sensitivity > 92% and specificity > 90% for tuberculous pleurisy.

• Chest Radiography (CXR): Identifies apical fibrocavitary disease, traction bronchiectasis, mediastinal/hilar lymphadenopathy, or diffuse 1–2 mm "millet seed" hematogenous seeding (miliary TB).
• CSF Analysis: Classic tuberculous meningitis triad: marked lymphocytic pleocytosis (100–500/µL), elevated protein (1.0–5.0 g/L), and profound hypoglycorrhachia (CSF/plasma glucose ratio < 0.30).
• Complete Blood Count (CBC): Evaluates normocytic normochromic anemia of chronic disease, leukocytosis, or peripheral monocytosis.
• Inflammatory Markers (CRP, ESR): Markedly elevated ESR (> 80–100 mm/h) is a frequent accompaniment of active tuberculosis.